Neutralizing Antibodies to Interferon Beta: Assessment of Their Clinical and Radiographic Impact: An Evidence Report: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 69:1552-1553, Sorenson,P.S. &Bertolotto,A., 2007
How Effective Are Disease-Modifying Drugs in Delaying Progression in Relapsing-Onset MS?
Neurol 69:1498-1507, Brown,M.G.,et al, 2007
Compulsive Singing: Another Aspect of Punding in Parkinsons Disease
Ann Neurol 62:525-528, Bonvin,C.,et al, 2007
Psychosis Related to Ropinirole
Am J Psychiatry 163:546-547, Perea,E.,et al, 2006
Multiple Diagnostic Tests Are Needed to Assess Multiple Causes of Dementia
Arch Neurol 63:144-146,146, Rikkert,M.G.M.O.,et al, 2006
The "Eye-of-the-Tiger" Sign is Not Pathognomonic of the PANK2 Mutation
Arch Neurol 63:292-293, Kumar,N.,et al, 2006
Safety and Tolerability of Interferon Beta-1b in Pediatric Multiple Sclerosis
Neurol 66:472-476, Banwell,B.,et al, 2006
Left Insular Stroke is Associated with Adverse Cardiac Outcome
Neurol 66:477-483, Laowattana,S.,et al, 2006
Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis
NEJM 354:911-923,965, Rudick,R.A.,et al, 2006
IM Interferon B-1a Delays Definite Multiple Sclerosis 5 Years After a First Demyelinating Event
Neurol 66:678-684, CHAMPIONS Study Group, 2006
Hiccups Associated with Dopamine Agonists in Parkinson Disease
Neurol 66:774-775, Sharma,P.,et al, 2006
Syncope and Falls Due to Timolol Eye Drops
BMJ 332:960-961, Mller,M.E.,et al, 2006
Prospective Prevalence of Pathologic Gambling and Medication Association in Parkinson Disease
Neurol 66:1750-1752, Voon,V.,et al, 2006
Interferon beta-1a Treatment in Childhood and Juvenile-Onset Multiple Sclerosis
Neurol 67:511-513, Tenembaum,S.N. &Segura,M.J., 2006
Restless Legs Syndrome: Is Treatable But Under-Recognised
BMJ 333:457-458, Medcalf,P. &Bhatia,K.P., 2006
Efficacy and Safety of Pramipexole in Restless Legs Syndrome
Neurol 67:1034-1039, Winkelman,J.W.,et al, 2006
Efficacy of Cabergoline in Restless Legs Syndrome, A Placebo-Controlled Study with Polysomnography (CATOR)
Neurol 67:1040-1046, Oertel,W.H.,et al, 2006
Dopamine Agonists and Cardiac Valvulopathy in Parkinson Disease: A Case-Control Study
Neurol 67:1225-1229, Yamamoto,M.,et al, 2006
Treatment With Interferon beta-1b Delays Conversion to Clinically Definite and McDonald MS in Patients With Clinically Isolated Syndromes
Neurol 67:1242-1249, Kappos,L.,et al, 2006
Acromegaly
NEJM 355:2558-2573, Melmed,S., 2006
PET of Brain Amyloid and Tau in Mild Cognitive Impairment
NEJM 355:2652-2663, Small,G.W.,et al, 2006
The role of radiotracer imaging in Parkinson disease
Neurol 64:208-215, Ravina, B., et al, 2005
A Trial of Metoclopramide vs Sumatriptan for the Emergency Department Treatment of Migraines
Neurol 64:463-468, Friedman, B.W., et al, 2005
Treatment of Early Onset Multiple Sclerosis With Subcutaneous Interferon Beta-1a
Neurol 64:888-890, 778, Pohl,D., et al, 2005
Neurocardiogenic Syncope
NEJM 352:1004-1010, Grubb, B.P., 2005
FDA Public Health advisory-Suspended Marketing of Tysabri (natalizumab)
www.fda.gov/cder/drug/advisory/natalizumab.htm.,(Feb 28), US Food and Drug Admin., 2005
Enhanced Benefit of Increasing Interferon Beta-1a Dose and Frequency in Relapsing Multiple Sclerosis
Arch Neurol 62:785-792, Schwid,S.R.,et al, 2005
Practice Parameter:Therapies for Essential Tremor
Neurol 64:2008-2020, Zesiewicz,T.A.,et al, 2005
Neutralizing Anti-IFN-B Antibodies
Neurol 65:6-8, Giovannoni,G.&Goodman,A., 2005
Life-Threatening Acute Pancreatitis Associated with Interferon Beta-1a Treatment in Multiple Sclerosis
Neurol 65:170-171, Midgard,R.,et al, 2005
Pleuropulmonary Fibrosis After Long-term Treatment With the Dopamine Agonist Pergolide for Parkinson Disease
Arch Neurol 62:1290-1295, Tintner,R.,et al, 2005
Sudden Uncontrollable Somnolence and Medication Use in Parkinson Disease
Arch Neurol 62:1242-1248, Avorn,J.,et al, 2005
Polyneuropathy Associated with Interferon Beta Treatment in Patients with Multiple Sclerosis
Neurol 65:456-458, Ekstein,D.,et al, 2005
Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis
NEJM 353:369-374,414,432, Kleinschemidt-DeMasters,B.K. &Tyler,K.L., 2005
Diagnosis and Initial Management of Parkinsons Disease
NEJM 353:1021-1027, Nutt,J.G.&Wooten,G.F., 2005
Pathological Gambling Caused by Drugs Used to Treat Parkinson Disease
Arch Neurol 62:1377-1381, Dodd,M.L.,et al, 2005
Pregnancy Outcomes During Treatment with Interferon Beta-1a in Patients with Multiple Sclerosis
Neurol 65:802-806, Sandberg-Wollheim,M.,et al, 2005
The Reproductive Effects of Beta Interferon Therapy in Pregnancy, A longitudinal Cohort
Neurol 65:807-811,788, Boskovic,R.,et al, 2005
Tetraparesis Associated with Colchicine is Probably Due to Inhibition by Verapamil of the P-glycoprotein Efflux Pump in the Blood-Brain Barrier
BMJ 331:513, Troger,U.,et al, 2005
Cabergoline-Related Severe Restrictive Mitral Regurgitation
NEJM 353:1974-1975, Rosen,C.J., 2005
Verapamil Induced Gingival Enlargement in Cluster Headache
JNNP 76:124-127, Matharu,M.S.,et al, 2005
Parenteral Metoclopramide for Acute Migraine: Meta-Analysis of Randomised Controlled Trials
BMJ 329:1369-1372, Colman,I.,et al, 2004
Effective Cabergoline Treatment in Idiopathic Restless Legs Syndrome
Neurol 63:2272-2279, Stiasny-Kolster,K.,et al, 2004
Levodopa and the Progression of Parkinson's Disease
NEJM 351:2498-2508, The Parkinson Study Group, 2004
MR Spectroscopy in the Diagnosis of Cerebral Amyloid Angiopathy Presenting as a Brain Tumor
AJNR 25:1705-1708, Safriel,Y.,et al, 2004
Imaging Cerebral Atrophy:Normal Ageing to Alzheimer's Disease
Lancet 363:392-394, Fox,N.C.&Schott,J.M., 2004
Liver Injury Associated with the B-Interferons for MS
Neurol 62:628-631, Tremlett,H.L.,et al, 2004
Ropinirole in Gilles de la Tourette Syndrome
Neurol 62:1626-1627, Anea,M.H.,et al, 2004
Efficacy of Pergolide in Treatment of Restless Legs Syndrome
Neurol 62:1391-1397, Trenkwalder,C.,et al, 2004
Treatment of Parkinson's Disease with Pergolide and Relation to Restrictive Valvular Heart Disease
Lancet 363:1179-1183, Van Camp,G.,et al, 2004